Sector News

Novo opens ‘greenfield’ insulin plant in Russia

April 13, 2015
Life sciences
Novo Nordisk has opened a new manufacturing facility in Russia for formulation and filling of modern insulin destined for the treatment of diabetes.
 
Located at the Technopark Grabtsevo in the Kaluga region of Russia, the plant is the first and only greenfield facility for manufacturing modern insulin in the county, with environmental targets for CO² emission, water consumption and use of energy, according to the Danish drugmaker.
 
Around 10 million people in Russia are thought to have diabetes, and Novo says its move will ensure availability of high-quality modern insulins to patients. 
 
“I am convinced that the new facility will have a significant impact on improving the quality of life for people with diabetes in Kaluga as well as in the rest of Russia,” said Kaluga Region Governor, Anatoly Artamonov.
 
Novo currently also has production sites in Denmark, Brazil, China, France and the US.
 
By Selina McKee
 
Source: Pharma Times

Related News

February 28, 2021

UCB taps Microsoft to accelerate drug discovery, clinical trials

Life sciences

The deal will see Microsoft use its capabilities in computational services, cloud computing and artificial intelligence to support drug discovery and development at UCB.

February 28, 2021

GSK to close two UK antibiotics manufacturing sites

Life sciences

The planned closures come as GSK has agreed to sell its cephalosporins antibiotics business to Sandoz, a division of Swiss pharma firm Novartis, for as much as US$500m.

February 28, 2021

Colorcon launches TiO2-free supplement coating

Life sciences

“The launch of these new formulations provides the nutritional market with much-needed alternative coating systems that address clean label consumer preferences and are easy to implement,” says Kelly Boyer, vice president film coatings at Colorcon.

Send this to a friend